Ibrutinib resistance in chronic lymphocytic leukemia

New England Journal of Medicine

Volumn 370, Issue 24, 2014, Pages 2352-2354

  Furman, Richard R ^a   Cheng, Shuhua ^a   Lu, Pin ^b   Setty, Menu ^c   Perez, Alexendar R ^c   Guo, Ailin ^b   Racchumi, Joelle ^a   Xu, Guozhou ^d   Wu, Hao ^d   Ma, Jiao ^a   Steggerda, Susanne M ^e   Coleman, Morton ^a   Leslie, Christina ^c   Wang, Y Lynn ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e PHARMACYCLICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; BRUTON TYROSINE KINASE; COMPLEMENTARY DNA; CYSTEINE; GENOMIC DNA; IBRUTINIB; SERINE; THIOL DERIVATIVE; THYMIDINE;

ADULT; ALLELE; AMINO ACID SUBSTITUTION; BLOOD SAMPLING; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; COVALENT BOND; DISEASE COURSE; DRUG CONCENTRATION; DRUG DOSE ESCALATION; DRUG PROTEIN BINDING; DRUG RESPONSE; ELECTROPHORESIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; LETTER; LYMPHADENOPATHY; LYMPHOCYTE COUNT; MAXIMAL INHIBITORY CONCENTRATION; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; RNA SEQUENCE; TREATMENT FAILURE;

DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; PHOSPHORYLATION; POINT MUTATION; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; RECEPTORS, ANTIGEN, B-CELL; RECURRENCE; SEQUENCE ANALYSIS, DNA;

EID: 84902137363     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1402716     Document Type: Letter

References (6)

1. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31:88-94.
2. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:32-42. [Erratum, N Engl J Med 2014;370:786.]
3. Cheng S, Ma J, Guo A, et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia 2014;28:649-57.
4. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011;117:6287-96.
5. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010;107:13075-80.
6. Woyach JA, Furman RR, Liu T-M, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014;370:2286-94.